IRWD missed EPS expectations by 194.12%
May 07, 2025, 10:32 PM
0.00%
What does IRWD do
Ironwood Pharmaceuticals, based in Boston, develops GI products including LINZESS for IBS-C and CIC, and is advancing treatments like apraglutide for rare GI diseases and IW-3300 for visceral pain conditions. The company, which went public in 2010, employs 267 people.
Ironwood Pharmaceuticals (IRWD) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ironwood Pharmaceuticals's actual EPS was -$0.14, missing the estimate of -$0.05 per share, resulting in a -194.12% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.